The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about many questions as hospitals and blood centers prepare to order the testing. We've put together a FAQ document to clarify what we know today. We will update the document as we get more information on existing questions and as new questions get asked, and will update the blog with the revised FAQ document.
Thanks for your support as we work to rapidly get this testing available to you. You can find the FAQ document here: CTS COVID-19 Questions and Answers
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...